Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(04): 443-448
DOI: 10.1055/s-0042-1747679
Original Article

Serum Irisin Levels and Its Relationship with Spasticity Severity in Chronic Stroke Patients

Ercan Kaydok 
1   Department of Physical Medicine and Rehabilitation, Niğde Ömer Halisdemir University Faculty of Medicine, Niğde, Turkey
,
Ismail Sari
2   Department of Biochemistry, Niğde Ömer Halisdemir University Faculty of Medicine, Niğde, Turkey
,
Serpil Erşan
2   Department of Biochemistry, Niğde Ömer Halisdemir University Faculty of Medicine, Niğde, Turkey
,
Esin Benli Küçük
2   Department of Biochemistry, Niğde Ömer Halisdemir University Faculty of Medicine, Niğde, Turkey
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective Irisin is a myokine released from muscles by exercise and it has been shown to be a prognostic indicator in acute stroke patients. However, irisin's relationship with the chronic phase of stroke and spasticity has not been studied yet. We aimed to determine the serum level of irisin to examine its relationship with the functional status and severity of spasticity in patients with chronic stroke, and to compare these with healthy controls.

Materials and Methods A total of 70 (35 chronic stroke and 35 control patients) patients were included in the study. The blood serum irisin levels of the patients and the controls were evaluated using enzyme-linked immunosorbent assay method, their functional status was evaluated with the modified Rankin scale (mRS), and spasticity severity using the modified Ashworth scale (MAS).

Results The mean serum irisin levels of the stroke and the control groups were 6.20 ± 2.2 and 5.45 ± 2.3, respectively, and there was no statistically significant difference (p > 0.05). No significant correlation was found between the serum level of irisin and the severity of spasticity and functional status, assessed by the mRS in stroke patients.

Conclusion These results showed that irisin levels in chronic stroke patients were similar to controls, and there was no relationship between the severity of spasticity and functional status and irisin level.

Keywords

Irisin - stroke - spasticity - functional outcomes

Financial Support

None.




Publication History

Article published online:
28 June 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bonita R, Beaglehole R, Asplund K. The worldwide problem of stroke. Curr Opin Neurol 1994; 7 (01) 5-10
    CrossrefPubMedGoogle Scholar
  • 2 Hankey GJ. Stroke: how large a public health problem, and how can the neurologist help?. Arch Neurol 1999; 56 (06) 748-754
    CrossrefPubMedGoogle Scholar
  • 3 Romero JR. Prevention of ischemic stroke: overview of traditional risk factors. Curr Drug Targets 2007; 8 (07) 794-801
    CrossrefPubMedGoogle Scholar
  • 4 Boström P, Wu J, Jedrychowski MP. et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481 (7382): 463-468
    CrossrefPubMedGoogle Scholar
  • 5 Dun SL, Lyu RM, Chen YH, Chang JK, Luo JJ, Dun NJ. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience 2013; 240: 155-162
    CrossrefPubMedGoogle Scholar
  • 6 Li DJ, Li YH, Yuan HB, Qu LF, Wang P. The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism 2017; 68: 31-42
    CrossrefPubMedGoogle Scholar
  • 7 Wu H, Guo P, Jin Z. et al. Serum levels of irisin predict short-term outcomes in ischemic stroke. Cytokine 2019; 122: 154303 DOI: 10.1016/j.cyto.2018.02.017.
    CrossrefPubMedGoogle Scholar
  • 8 Timmons JA, Baar K, Davidsen PK, Atherton PJ. Is irisin a human exercise gene?. Nature 2012; 488 (7413): discussion E10–E11 E9-E10 DOI: 10.1038/nature11364.
    CrossrefPubMedGoogle Scholar
  • 9 Kurdiova T, Balaz M, Mayer A. et al. Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes. Peptides 2014; 56: 1-7
    CrossrefPubMedGoogle Scholar
  • 10 Hofmann T, Elbelt U, Ahnis A, Kobelt P, Rose M, Stengel A. Irisin levels are not affected by physical activity in patients with anorexia nervosa. Front Endocrinol (Lausanne) 2014; 4: 202
    CrossrefPubMedGoogle Scholar
  • 11 Albright AL, Pollack IF, Adelson PD. Principles and Practice of Pediatric Neurosurgery. 2nd edition.. New York: Thieme; 2008: 1121-1124
    Google Scholar
  • 12 Goldstein EM. Spasticity management: an overview. J Child Neurol 2001; 16 (01) 16-23
    CrossrefPubMedGoogle Scholar
  • 13 Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67 (02) 206-207
    CrossrefPubMedGoogle Scholar
  • 14 Zhao H, Collier JM, Quah DM, Purvis T, Bernhardt J. The modified Rankin Scale in acute stroke has good inter-rater-reliability but questionable validity. Cerebrovasc Dis 2010; 29 (02) 188-193
    CrossrefPubMedGoogle Scholar
  • 15 Jin Z, Guo P, Li X, Ke J, Wang Y, Wu H. Neuroprotective effects of irisin against cerebral ischemia/ reperfusion injury via Notch signaling pathway. Biomed Pharmacother 2019; 120: 109452 DOI: 10.1016/j.biopha.2019.109452.
    CrossrefPubMedGoogle Scholar
  • 16 Jin Y, Sumsuzzman DM, Choi J, Kang H, Lee SR, Hong Y. Molecular and functional interaction of the myokine irisin with physical exercise and Alzheimer's disease. Molecules 2018; 23 (12) 3229 . Published 2018 Dec 7. DOI: 10.3390/molecules23123229.
    CrossrefPubMedGoogle Scholar
  • 17 Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology 2013; 80 (3, Suppl 2): S13-S19
    CrossrefPubMedGoogle Scholar
  • 18 Opheim A, Danielsson A, Alt Murphy M, Persson HC, Sunnerhagen KS. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil 2014; 93 (10) 884-896
    CrossrefPubMedGoogle Scholar
  • 19 Mirbagheri MM, Rymer WZ, Tsao C, Settle K. Evolution of reflexive and muscular mechanical properties in stroke-induced spasticity. Conf Proc IEEE Eng Med Biol Soc 2005; 2005: 4393-4395
    PubMedGoogle Scholar
  • 20 Tu WJ, Qiu HC, Cao JL, Liu Q, Zeng XW, Zhao JZ. Decreased concentration of irisin is associated with poor functional outcome in ischemic stroke. Neurotherapeutics 2018; 15 (04) 1158-1167
    CrossrefPubMedGoogle Scholar
  • 21 Guo X, Xuan X, Zhao B. et al. Irisin in elderly people with hypertension, diabetes mellitus type 2, and overweight and obesity. Int J Diabetes Dev Countries 2020; 40: 196-202
    CrossrefGoogle Scholar
  • 22 Çelik HT, Akkaya N, Erdamar H. et al. The effects of valsartan and amlodipine on the levels of Irisin, Adropin, and Perilipin. Clin Lab 2015; 61 (12) 1889-1895
    PubMedGoogle Scholar
  • 23 Crujeiras AB, Zulet MA, Lopez-Legarrea P. et al. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism 2014; 63 (04) 520-531
    CrossrefPubMedGoogle Scholar
  • 24 Chen N, Li Q, Liu J, Jia S. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review. Diabetes Metab Res Rev 2016; 32 (01) 51-59
    CrossrefPubMedGoogle Scholar
  • 25 Choi YK, Kim MK, Bae KH. et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100 (01) 96-101
    CrossrefPubMedGoogle Scholar
  • 26 Park KH, Zaichenko L, Brinkoetter M. et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. [published correction appears in J Clin Endocrinol Metab. 2014 May;99(5):1910] J Clin Endocrinol Metab 2013; 98 (12) 4899-4907
    CrossrefPubMedGoogle Scholar